Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 14, 2015; 21(14): 4111-4120
Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4111
Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4111
Table 2 Described methods of testing for gastrointestinal cancer and accuracy of commercially available tests based on recent evidence (point-of-care)
Technology | Commercial available POC device | POC sensitivity | POC specificity | Level of evidence | Papers retrieved in primary search (n) |
Occult blood | Yes | 79%[25] | 94%[25] | 1 | 10[20,22,34,66-72] |
Fecal proteins | Yes | 83%[33] (calprotectin) | 84%[33] (calprotectin) | 2 | 3[34,73,74] |
Volatile organic compounds | No | 0 | |||
Pyruvate kinase isoenzyme type M2 | Yes | 80.3%[48] | 95.2%[48] | 1 | 1[72] |
Tumour markers | No | 6[47,49,68,75-77] | |||
DNA mutation analysis | No | 4[56,76,78,79] | |||
Multitarget stool DNA test | No | 0 |
- Citation: Huddy JR, Ni MZ, Markar SR, Hanna GB. Point-of-care testing in the diagnosis of gastrointestinal cancers: Current technology and future directions. World J Gastroenterol 2015; 21(14): 4111-4120
- URL: https://www.wjgnet.com/1007-9327/full/v21/i14/4111.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i14.4111